The prevailing offseason narrative is that David Stearns doesn't want to send, but the New York Mets $50 million AAV offer to Kyle Tucker turns the argument on its head.

Siren plans to initiate a first-in-human clinical study in adult patients with recurrent high-grade glioma. This advancement builds on the Company’s broader Universal AAV Immuno-Gene Therapy platform, ...

10 biggest NY Mets contracts AAV in team history ...

Adeno-associated virus (AAV) vectors have become widely recognized as a fundamental tool in gene therapy, primarily due to their potential as a delivery system for the treatment of genetic disorders.

Separating full and empty adeno-associated virus (AAV) capsids during the manufacture of single-gene therapies remains a significant challenge. Ultracentrifugation and anion exchange chromatography ...